Erschienen in:
01.01.2007 | Original article
Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET
verfasst von:
Katja Havu-Aurén, Johanna Kiiski, Kaisa Lehtiö, Olli Eskola, Martti Kulvik, Ville Vuorinen, Vesa Oikonen, Jyrki Vähätalo, Juha Jääskeläinen, Heikki Minn
Erschienen in:
European Journal of Nuclear Medicine and Molecular Imaging
|
Ausgabe 1/2007
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Meningiomas and schwannomas associated with neurofibromatosis 2 (NF2) are difficult to control by microsurgery and stereotactic radiotherapy alone. Boron neutron capture therapy (BNCT) is a chemically targeted form of radiotherapy requiring increased concentration of boron-10 in tumour tissue. PET with the boron carrier 4-borono-2-[18F]fluoro-L-phenylalanine ([18F]FBPA) allows investigation of whether 4-borono-L-phenylalanine (BPA) concentrates in NF2 tumours, which would make BNCT feasible.
Methods
We studied dynamic uptake of [18F]FBPA in intracranial meningiomas (n=4) and schwannomas (n=6) of five sporadic and five NF2 patients. Tracer input function and cerebral blood volume were measured. [18F]FBPA uptake in tumour and brain was assessed with a three-compartmental model and graphical analysis. These, together with standardised uptake values (SUVs), were used to define tumour-to-brain [18F]FBPA tissue activity gradients.
Results
Model fits with three parameters K
1 (transport), k
2 (reverse transport) and k
3 (intracellular metabolism) were found to best illustrate [18F]FBPA uptake kinetics. Maximum SUV was two- to fourfold higher in tumour as compared with normal brain and independent of NF2 status. The increased uptake was due to higher transport of [18F]FBPA in tumour. In multiple-time graphical analysis (MTGA, Gjedde-Patlak plot) the tumour-to-brain [18F]FBPA influx constant (K
i -MTGA) ratios varied between 1.8 and 5.4 in NF2-associated tumours while in sporadic tumours the ratio was 1–1.4.
Conclusion
[18F]FBPA PET offers a viable means to evaluate BPA uptake in meningiomas and schwannomas in NF2. Based on our results on tumour uptake of [18F]FBPA, some of these benign neoplasms may be amenable to BNCT.